DPP4 and Recurrent upper respiratory tract infections: Similarly, the majority of meta-analysis pooling results from clinical trials suggest that there is not a significant risk of all-cause infection, upper respiratory tract infections, or pneumonia associated with using a DPP4 inhibitor.